Moomoo AI 已提取核心信息
AbbVie Inc., a global biopharmaceutical company, has announced the issuance of multiple series of senior notes with varying maturity dates and interest rates. The notes are unsecured, unsubordinated obligations and will rank equally with the company's existing and future unsecured, unsubordinated indebtedness. Interest on each series is payable semi-annually, commencing in 2024. The company intends to use the net proceeds from the sale of the notes to repay loans under the New Term Facility, fund the Cerevel merger consideration, repay outstanding borrowings under the commercial paper program, pay related fees and expenses, and for general corporate purposes. The offering is managed by joint book-running managers Morgan Stanley, J.P. Morgan, BofA Securities, and Citigroup. The notes will not be listed on any securities exchange, and currently, there is no public market for the notes. The date of the prospectus supplement is February 21, 2024.
AbbVie Inc., a global biopharmaceutical company, has announced the issuance of multiple series of senior notes with varying maturity dates and interest rates. The notes are unsecured, unsubordinated obligations and will rank equally with the company's existing and future unsecured, unsubordinated indebtedness. Interest on each series is payable semi-annually, commencing in 2024. The company intends to use the net proceeds from the sale of the notes to repay loans under the New Term Facility, fund the Cerevel merger consideration, repay outstanding borrowings under the commercial paper program, pay related fees and expenses, and for general corporate purposes. The offering is managed by joint book-running managers Morgan Stanley, J.P. Morgan, BofA Securities, and Citigroup. The notes will not be listed on any securities exchange, and currently, there is no public market for the notes. The date of the prospectus supplement is February 21, 2024.
全球生物制药公司艾伯维公司（AbbVie Inc.）宣布发行多个到期日和利率各不相同的优先票据。这些票据是无抵押的非次级债务，将与公司现有和未来的无抵押、无次级债务同等排名。从2024年开始，每个系列的利息每半年支付一次。该公司打算将出售票据的净收益用于偿还新定期融资机制下的贷款，为Cerevel合并对价提供资金，偿还商业票据计划下的未偿借款，支付相关费用和开支，以及用于一般公司用途。此次发行由联席账面运营经理摩根士丹利、摩根大通、美银证券和花旗集团管理。这些票据不会在任何证券交易所上市，目前，这些票据没有公开市场。招股说明书补充材料的发布日期为2024年2月21日。
全球生物制药公司艾伯维公司（AbbVie Inc.）宣布发行多个到期日和利率各不相同的优先票据。这些票据是无抵押的非次级债务，将与公司现有和未来的无抵押、无次级债务同等排名。从2024年开始，每个系列的利息每半年支付一次。该公司打算将出售票据的净收益用于偿还新定期融资机制下的贷款，为Cerevel合并对价提供资金，偿还商业票据计划下的未偿借款，支付相关费用和开支，以及用于一般公司用途。此次发行由联席账面运营经理摩根士丹利、摩根大通、美银证券和花旗集团管理。这些票据不会在任何证券交易所上市，目前，这些票据没有公开市场。招股说明书补充材料的发布日期为2024年2月21日。
有用
没用
该公告为独立文件：